BOD - Trademark Details
Status: 602 - Abandoned-Failure To Respond Or Late Response
Serial Number
88835504
Word Mark
BOD
Status
602 - Abandoned-Failure To Respond Or Late Response
Status Date
2021-09-17
Filing Date
2020-03-16
Mark Drawing
5000 - Illustration: Drawing with word(s)/letter(s)/number(s) in Stylized form
Typeset
Attorney Name
Law Office Assigned Location Code
M80
Employee Name
FOSTER, ALEXANDRA M.
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the word BOD in a stylized font.
Goods and Services
Nutritional supplements; dietary supplements; vitamin supplements; natural healthcare preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; natural pharmaceutical preparations for general health and well-being and for the treatment of metabolic diseases and disorders, namely, diabetes, type II diabetes, nephropathy, inflammation of the intestine, neuroinflammatory disorders, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, obesity associated with diabetes, and for the treatment of pain, neuropathic pain, neurogenic pain, cancer pain, peri-operative pain, oncology, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalized epilepsy with febrile seizures plus (GEFS+), Dup15q syndrome, and Doose syndrome, bladder disfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, Lennox-Gastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory connective tissue diseases, arthritis, neurodegenerative diseases, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, cerebral palsy, brain, movement, ocular motility, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness, AIDS (HIV) and AIDS wasting, asthma, breathing disorders, hepatitis C, migraines, multiple sclerosis, analgesia, Tourette syndrome, bulimia, psychiatric disorders, namely, bipolar disorder, dementia, anxiety disorders, Alzheimer's disease, schizophrenia, and drug, alcohol and nicotine abuse, autism, nausea, vomiting, loss of appetite, muscle tension, muscle spasms, epilepsy, glaucoma, arthritis, Parkinson's disease, gastrointestinal illness, anxiety, bi-polar disorder, depression, insomnia, and for topical treatment of skin inflammation, namely, eczema, psoriasis, atopic dermatitis, acne, rosacea, lichen planus, bullous pemphigold, vasculitis, granuloma annulare and erythroderma; any the foregoing containing hemp extracts are derived from Cannabis sativa L. with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2020-03-20
Primary Code
005
Correspondences
Name
Thomas L. Holt
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2020-03-19 | NEW APPLICATION ENTERED IN TRAM |
2020-03-20 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2020-06-08 | ASSIGNED TO EXAMINER |
2020-06-09 | ASSIGNED TO EXAMINER |
2020-08-06 | TEAS VOLUNTARY AMENDMENT RECEIVED |
2020-08-06 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
2020-08-31 | ASSIGNED TO EXAMINER |
2020-09-05 | NON-FINAL ACTION WRITTEN |
2020-09-05 | NON-FINAL ACTION E-MAILED |
2020-09-05 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2021-03-03 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2021-03-03 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2021-03-04 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2021-03-06 | FINAL REFUSAL WRITTEN |
2021-03-06 | FINAL REFUSAL E-MAILED |
2021-03-06 | NOTIFICATION OF FINAL REFUSAL EMAILED |
2021-09-17 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
2021-09-17 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |